Plus Therapeutics Inc (NAS:PSTV)
$ 1.16 0.08 (7.41%) Market Cap: 6.37 Mil Enterprise Value: 4.98 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Plus Therapeutics, Inc. - Special Call Transcript

Nov 19, 2020 / 09:30PM GMT
Release Date Price: $32.85 (-6.01%)
Marc H. Hedrick
Plus Therapeutics, Inc. - President, CEO & Director

Good afternoon. Welcome to our investor update call on our Phase I ReSPECT trial for recurrent glioblastoma. As a reminder, please review our forward-looking statements language that can be found in this investor deck or other investor-oriented presentations.

My name is Marc Hedrick. I'm President and CEO of Plus Therapeutics. I'll lead the call through our planned 1-hour agenda. First, I'll present a brief overview on Plus, then the team will talk about recurrent glioblastoma as a disease target. And then we'll talk about the results of the ReSPECT trial thus far, and then we'll hear from a patient. Following the patient, we'll then have time for Q&A.

Joining me this afternoon are Dr. Gregory Stein, Senior Vice President of Clinical Development at Plus Therapeutics; and also, we're fortunate to have Dr. Andrew Brenner, Associate Professor of Medicine, Neurology and Neurosurgery at UT Health Science Center at San Antonio.

So with regard to Plus Therapeutics, our focus is on the discovering, developing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot